These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 39277035)

  • 1. Application of MIDD to accelerate the development of anti-infectives: Current status and future perspectives.
    Mak WY; He Q; Yang W; Xu N; Zheng A; Chen M; Lin J; Shi Y; Xiang X; Zhu X
    Adv Drug Deliv Rev; 2024 Nov; 214():115447. PubMed ID: 39277035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.
    Rayner CR; Smith PF; Andes D; Andrews K; Derendorf H; Friberg LE; Hanna D; Lepak A; Mills E; Polasek TM; Roberts JA; Schuck V; Shelton MJ; Wesche D; Rowland-Yeo K
    Clin Pharmacol Ther; 2021 Apr; 109(4):867-891. PubMed ID: 33555032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-informed drug development in pediatric, pregnancy and geriatric drug development: States of the art and future.
    Wu YE; Zheng YY; Li QY; Yao BF; Cao J; Liu HX; Hao GX; van den Anker J; Zheng Y; Zhao W
    Adv Drug Deliv Rev; 2024 Aug; 211():115364. PubMed ID: 38936664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of Model-Informed Drug Development in Dose Selection and Optimization for siRNA Therapies.
    Yuan Y; Li L; Earp J; Ma L; Bhattaram VA; Sharma V; Tong A; Wang Y; Liu J; Zhu H
    J Clin Pharmacol; 2024 Jul; 64(7):799-809. PubMed ID: 38426370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities.
    Al-Huniti N; Feng Y; Yu JJ; Lu Z; Nagase M; Zhou D; Sheng J
    CPT Pharmacometrics Syst Pharmacol; 2020 Aug; 9(8):419-427. PubMed ID: 32589767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status and challenges of model-informed drug discovery and development in China.
    Wang Y; Ji J; Yao Y; Nie J; Xie F; Xie Y; Li G
    Adv Drug Deliv Rev; 2024 Nov; 214():115459. PubMed ID: 39389423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Modern Curriculum for Training Scientists in Model-Informed Drug Development: Progress Report on FDA Grant to Train Regulatory Scientists.
    Barrett JS; Romero K; Rayner C; Gastonguay M; Pillai GC; Tannenbaum S; Kern S; Selich M; Francisco D
    Clin Pharmacol Ther; 2024 Aug; 116(2):289-294. PubMed ID: 39012325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model-Informed Drug Development Approaches to Assist New Drug Development in the COVID-19 Pandemic.
    Xiong Y; Fan J; Kitabi E; Zhang X; Bi Y; Grimstein M; Yang Y; Earp JC; Zheng N; Liu J; Wang Y; Zhu H
    Clin Pharmacol Ther; 2022 Mar; 111(3):572-578. PubMed ID: 34807992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Model-Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling.
    Bi Y; Liu J; Li L; Yu J; Bhattaram A; Bewernitz M; Li RJ; Liu C; Earp J; Ma L; Zhuang L; Yang Y; Zhang X; Zhu H; Wang Y
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S104-S111. PubMed ID: 31502691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consideration of a Credibility Assessment Framework in Model-Informed Drug Development: Potential Application to Physiologically-Based Pharmacokinetic Modeling and Simulation.
    Kuemmel C; Yang Y; Zhang X; Florian J; Zhu H; Tegenge M; Huang SM; Wang Y; Morrison T; Zineh I
    CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):21-28. PubMed ID: 31652029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model-Informed Drug Development in Pediatric Dose Selection.
    Bi Y; Liu J; Li F; Yu J; Bhattaram A; Bewernitz M; Li RJ; Ahn J; Earp J; Ma L; Zhuang L; Yang Y; Zhang X; Zhu H; Wang Y
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S60-S69. PubMed ID: 34185906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case-study of model-informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II.
    Knöchel J; Nilsson C; Carlsson B; Wernevik L; Hofherr A; Gennemark P; Jansson-Löfmark R; Isaksson R; Rydén-Bergsten T; Hamrén B; Rekić D
    CPT Pharmacometrics Syst Pharmacol; 2022 Dec; 11(12):1569-1577. PubMed ID: 36126230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making.
    Madabushi R; Seo P; Zhao L; Tegenge M; Zhu H
    Pharm Res; 2022 Aug; 39(8):1669-1680. PubMed ID: 35552984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An AI Approach to Generating MIDD Assets Across the Drug Development Continuum.
    Barrett JS; Goyal RK; Gobburu J; Baran S; Varshney J
    AAPS J; 2023 Jul; 25(4):70. PubMed ID: 37430126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opportunities and challenges for applying model-informed drug development approaches to gene therapies.
    Belov A; Schultz K; Forshee R; Tegenge MA
    CPT Pharmacometrics Syst Pharmacol; 2021 Apr; 10(4):286-290. PubMed ID: 33608998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug repurposing to overcome microbial resistance.
    Jampilek J
    Drug Discov Today; 2022 Jul; 27(7):2028-2041. PubMed ID: 35561965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program.
    Galluppi GR; Ahamadi M; Bhattacharya S; Budha N; Gheyas F; Li CC; Chen Y; Dosne AG; Kristensen NR; Magee M; Samtani MN; Sinha V; Taskar K; Upreti VV; Yang J; Cook J
    Clin Pharmacol Ther; 2024 Aug; 116(2):282-288. PubMed ID: 38519861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose Optimization Informed by PBPK Modeling: State-of-the Art and Future.
    Rowland Yeo K; Gil Berglund E; Chen Y
    Clin Pharmacol Ther; 2024 Sep; 116(3):563-576. PubMed ID: 38686708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Application of MIDD in Clinical Research of Antitumor Drugs].
    Yu M; Wang H
    Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):487-492. PubMed ID: 35899446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral Peptides in Antimicrobial Surface Coatings-From Current Techniques to Potential Applications.
    Jabeen M; Biswas P; Islam MT; Paul R
    Viruses; 2023 Feb; 15(3):. PubMed ID: 36992349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.